Saratov JOURNAL of Medical and Scientific Research
Home

Post-COVID-19 asthenic-vegetative syndrome

Year: 2022, volume 18 Issue: №1 Pages: 128-132
Heading: Тhematic supplement Article type: Original article
Authors: Melnikov K.N., Poverennova I.E., Kachkovsky M.A., Kuzmina T.M., Antonov A.I.
Organization: Medical University "Reaviz", Samara State Medical University
Summary:

Objective: to improved diagnosis and treatment of asthenic-vegetative syndrome in those who have undergone COVID-19 on the basis of studying the peculiarities of its course. Material and methods. Included in the study were 54 outpatient patients aged 21 to 59 years who underwent symptomatic laboratory-confirmed COVID-19. All patients underwent electrocardiography and laboratory studies. A questionnaire was used on the Wein Vegetative Dysfunction Scale, the Beck Depression Questionnaire, the Spielberg — Hanin Situational and Personality Anxiety Scale, the Brief Mental Status Assessment Scale (MMSE) at the first visit, and again at 1 and 3 months on the background of neuropro-tective therapy. Results. It was revealed that those who underwent COVID-19 develop asthenic-vegetative syndrome with asthenic and vegetal-dystonic manifestations and pronounced anxiety-depressive disorders in 100% of patients. Against the background of therapy, there was a significant decrease in the number and severity of asthenic manifestations (from 74.1 % of patients to 5.6%) and mental disorders (from 20.4% of patients to 3.7%), but the level of anxiety remained quite high (in 40.7% of patients). Conclusions. Treatment of patients with post COVID-19 asthenic-vegetative syndrome gives a faster effect in terms of stopping asthenic and cognitive impairment, and a delayed positive dynamics in relation to anxiety-depressive manifestations.

Keywords: asthenic-vegetative syndrome, COVID-19

Bibliography:
1. Tharakan S, Nomoto K, Miyashita S, Ishikawa K. Body temperature correlates with mortality in COVID-19 patients. Crit Care 2020; 24 (1): 298. DOI: 10.1186/s13054-020-03045-8.
2. Kiselevskiy M, Shubina I, Chikileva I, etal. Immune patho-genesis of COVID-19 Intoxication: storm or silence? Pharmaceuticals (Basel) 2020; 13(8): 166. DOI: 10.3390/ph13080166.
3. Weiss P, Murdoch DR. Clinical course and mortality risk of severe COVID-19. Lancet 2020; 395 (10229): 1014-15. DOI: 10.1016/S0140-6736(20)30633-4.
4. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol 2020; 45 (8): 100618. DOI: 10.1016/j. cpcardiol. 2020.100618.
5. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med 2021; 27 (4): 626-31. DOI: 10.1038/S41591 -021 -01292-y.
6. COVID-19 rapid guideline: managing the long-term effects of COVID-19 (NG188). London: National Institute for Health and Care Excellence; 2020. PMID: 33555768.
7. Nagashima S, Mendes MC, Camargo Martins AP, et al. Endothelial dysfunction and thrombosis in patients with COVID-19. Brief Report Arterioscler Thromb Vase Biol 2020; 40 (10): 2404-7. DOI: 10.1161/ATVBAHA. 120.314860.
8. Wijeratne T, Crewther S. Post-COVID 19 Neurological Syndrome (PCNS); a novel syndrome with challenges for the global neurology community. J Neurol Sci 2020; (419): 117179. DOI: 10.1016/j.jns.2020.117179.
9. Usov Kl, Yushkov GG. Neuropsychological aspects of post-covid syndrome. Scientific Papers Collection of the Angarsk State Technical University 2021; 1 (18): 231-5.
10. Sudre CH, Murray В, Varsavsky Т, et al. Attributes and predictors of long COVID. Nat Med 2021; 27 (4): 626-31. DOI: 10.1038/S41591 -021 -01292-y.
11. Belopasov VV, Yachou Y, Samoilova EM, Baklau-shev VP The Nervous System Damage in COVID-19. J Clin Practice 2020; 11 (2): 60-80. DOI: 10.17816/clinpract34851.
12. Camdessanche JP, Morel J, Pozzetto В, etal. COVID-19 may induce Guillain — Barre syndrome. Rev Neurol (Paris) 2020; 176 (6): 516-8. DOI: 10.1016/j.neurol.2020.04.003.
13. Carod-Artal FJ. Neurological complications of corona-virus and COVID-19. Rev Neurol 2020; 70 (9): 311-22. DOI: 10.33588/rn.7009.2020179.
14. Dani M, Dirksen A, Taraborrelli P, et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin Med (Lond) 2021; 21 (1): e63-e67. DOI: 10.7861 /clinmed.2020-0896.
15. Jaffri A, Jaffri UA. Post-intensive care syndrome and COVID-19: crisis after a crisis? Heart Lung 2020; 49 (6): 883-4. DOI: 10.1016/j.hrtlng.2020.06.006.
16. Reyes M, Dobbins JG, Nisenbaum R, et al. Chronic fatigue syndrome progression and self-defined recovery: evidence from the CDC surveillance system. J Chronic Fatigue Syndr 1999; (5): 7-17. DOI: 10.1300/J092v05n01_03.
17. Maquet D, Demoulin C, Crielaard JM. Chronic fatigue syndrome: A systematic review. Ann Readapt Med Phys 2006; 49 (6): 337-47, 418-27. DOI: 10.1016/j.annrmp.2006.03.011.
18. Zolotovskaya IA, Shatskaia PR, Davydkin IL, Shavlovskaya OA. Post-COVID-19 asthenic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry 2021; 121 (4): 25-30. DOI: 10.17116/jnevro202112104125.
19. Deng J, Zhou F, Hou W, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann NY Acad Sci 2021; 1486 (1): 90-111. DOI: 10.1111/nyas.14506.
20. El Sayed S, Shokry D, Gomaa SM. Post-COVID-19 fatigue and anhedonia: A cross-sectional study and their correlation to post-recovery period. Neuropsychopharmacol Rep 2021; 41 (1): 50-5. DOI: 10.1002/npr2.12154.

AttachmentSize
2022_01-1_128-132.pdf342.47 KB
All articles of the authors: Antonov A.I., Kachkovskiy M.A., Kuzmina T.M., Melnikov K.N., Poverennova I.E.

No votes yet